RxMP Therapeutics Announces Strategic Developments and Leadership Changes

RxMP Therapeutics Provides Corporate Update

RxMP Therapeutics, Inc. has recently made significant strides in its mission to create innovative therapies for hemorrhage and excessive bleeding. On June 9, 2025, the company announced a variety of updates, including a key cooperative research and development agreement with the U.S. Department of Defense (DoD) and the appointment of Shawna Khouri as the new Chief Operating Officer (COO).

Cooperative Research and Development Agreement

In March 2025, RxMP entered into a Cooperative Research and Development Agreement (CRADA) with the Institute of Surgical Research (ISR), part of the Defense Health Agency. This collaboration allows RxMP to provide its leading product candidate, RMP-402, along with vital research materials to the ISR. The focus of this agreement is to validate the effectiveness of RMP-402, which consists of red cell-derived lyophilized microparticles, in promoting coagulation function in large animal preclinical models suffering from polytrauma hemorrhage and shock.

The partnership with the DoD signifies the importance placed on advancing medical interventions designed to combat severe hemorrhaging and traumatic injuries. Dr. Rifat Pamukcu, President and CEO of RxMP, commented on how this collaboration enhances their capabilities in producing groundbreaking therapeutics that could benefit both civilians and military personnel.

FDA Manufacturing Process Agreement

Additionally, RxMP successfully reached a consensus with the FDA on its Good Manufacturing Practice (GMP) for the allogeneic version of RMP-402. Earlier this year, RxMP engaged in a Type C meeting with the FDA to discuss the finalization of their GMP manufacturing process prior to conducting further IND-enabling studies. The positive outcome allows the company to proceed with confidence towards large-scale manufacturing.

Leadership Expansion with Shawna Khouri

Moreover, RxMP recently appointed Shawna Khouri as the Chief Operating Officer. Khouri brings an extensive background in health and innovation, particularly in her previous role as Director for Health and Innovation Initiatives at Tulsa Innovation Labs, where she managed over $100 million in various funding projects. Her experience is anticipated to significantly contribute to RxMP’s operational strategy for its innovative drug platform focusing on hemostasis.

Dr. Pamukcu expressed enthusiasm regarding Khouri’s appointment, emphasizing how her expertise in finance and biomedical engineering will complement the ongoing expansion of their unique GMP manufacturing process.

Looking Ahead

The commitment of RxMP Therapeutics to advance in research and development, coupled with its strategic partnerships, underscores the potential for significant breakthroughs in the treatment of hemorrhage. As the company continues to grow and innovate, it aims not only to enhance civilian health outcomes but also to support the medical needs of armed forces.

For further information about their initiatives or to stay updated on RxMP's progress, you can visit their official website at www.rxmpt.com.